Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 6,437 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Clear all
Completed No phase listed Observational

Kidney Stone Structural Analysis By Helical Computed Tomography (CT)

NCT00169780
View directory record Official record
Conditions
Nephrolithiasis
Interventions
High definition helical CT (64 head scanner)
Radiation
Lead sponsor
Indiana Kidney Stone Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Oct 25, 2026, 11:47 AM EDT
Terminated Phase 3 Interventional

Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis

NCT05962788
View directory record Official record
Conditions
Adolescent Lupus Nephritis, Pediatric Lupus Nephritis
Interventions
voclosporin
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 25, 2026, 11:47 AM EDT
Completed Phase 4 Interventional Results available

Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

NCT00113269
View directory record Official record
Conditions
Kidney Transplantation
Interventions
basiliximab, rabbit anti-thymocyte globulin, tacrolimus, alemtuzumab, mycophenolate mofetil, steroids
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Oct 25, 2026, 11:47 AM EDT
Active, not recruiting Early Phase 1 Interventional

Tolerance Through Mixed Chimerism (Sip-Tego)

NCT06972069
View directory record Official record
Conditions
Kidney Failure, Transplant Recipient (Kidney), Transplant Tolerance, Immunosuppresion, Immunosuppression After Kidney Transplantation
Interventions
Combined Kidney/Bone Marrow Transplant, Donation of Kidney / Bone Marrow, Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart)
Procedure · Drug
Lead sponsor
Tatsuo Kawai, MD, PhD
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 11:47 AM EDT
Withdrawn Not applicable Interventional

Using Continuous Positive Airway Pressure to Reduce the Incidence of Acute Kidney Injury in Hospitalized Patients With Chronic Kidney Disease

NCT01859260
View directory record Official record
Conditions
Chronic Kidney Disease, Obstructive Sleep Apnea
Interventions
CPAP/autopap
Device
Lead sponsor
University of South Florida
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Oct 25, 2026, 11:47 AM EDT
Completed Not applicable Interventional

AKI Prevention and Early Intervention in VAD Patients Admitted for Acute Medical Events.

NCT03236103
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Clinical Recommendations
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 25, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

Hemodialysis.-Induced Hypotension Therapy for End Stage Kidney Disease

NCT05297786
View directory record Official record
Conditions
Hemodialysis Complication, Hypotension of Hemodialysis
Interventions
Lanadelumab Injection [Takhzyro], Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 25, 2026, 11:47 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide

NCT01932970
View directory record Official record
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
40
States / cities
Alhambra, California • Azusa, California • Bakersfield, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 25, 2026, 11:47 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

NCT03011450
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
K-877, Fenofibrate, Placebo (for K-877)
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
129
States / cities
Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 25, 2026, 11:47 AM EDT
Completed Not applicable Interventional

Assessing Novel Methods of Improving Patient Education of Nutrition

NCT00394576
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Internet-based nutrition module along with usual care, usual care
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 25, 2026, 11:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function

NCT06496217
View directory record Official record
Conditions
Renal Impairment
Interventions
MBX 2109
Drug
Lead sponsor
MBX Biosciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 25, 2026, 11:47 AM EDT
Completed Phase 2 Interventional

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

NCT00043368
View directory record Official record
Conditions
Melanoma, Breast Neoplasms, Carcinoma, Renal Cell, Lymphoma, T-Cell, Carcinoma, Non-Small-Cell Lung
Interventions
PF-3512676
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
31
States / cities
Berkely, California • Gilroy, California • Hollister, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Oct 25, 2026, 11:47 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

NCT04955743
View directory record Official record
Conditions
Melanoma, Renal Cell Carcinoma, Brain Metastases, PD1/PD-L1 Experienced, Pembrolizumab, Lenvatinib, Metastatic Melanoma
Interventions
Pembrolizumab, Lenvatinib
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 25, 2026, 11:47 AM EDT
Terminated Early Phase 1 Interventional Results available

Research Study of ATG and Rituximab in Renal Transplantation

NCT01318915
View directory record Official record
Conditions
Renal Transplant Recipients
Interventions
ATG, Rituximab, Tacrolimus, Sirolimus, MMF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 25, 2026, 11:47 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)

NCT06839235
View directory record Official record
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Interventions
ABO-101
Drug
Lead sponsor
Arbor Biotechnologies
Industry
Eligibility
6 Years to 64 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2043
U.S. locations
2
States / cities
Rochester, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 11:47 AM EDT
Not listed No phase listed Observational

Genetic Predictors of Renal Dysfunction Following Heart Transplantation

NCT01686191
View directory record Official record
Conditions
Heart Transplantation, Chronic Renal Insufficiency
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 25, 2026, 11:47 AM EDT
Completed Phase 3 Interventional

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

NCT00014391
View directory record Official record
Conditions
Cancer
Interventions
palivizumab, ribavirin
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 25, 2026, 11:47 AM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00601926
View directory record Official record
Conditions
Kidney Cancer
Interventions
bevacizumab
Biological
Lead sponsor
Paul Monk
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 25, 2026, 11:47 AM EDT
Recruiting Not applicable Interventional

Impact of Intraoperative Oxygenation Practices on Patient Outcomes

NCT07224243
View directory record Official record
Conditions
Surgeries Undergoing General Anesthesia
Interventions
Lower FiO2, Intermediate FiO2, Higher FiO2
Other
Lead sponsor
Frederic T Billings IV
Other
Eligibility
18 Years and older
Enrollment
54,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Ann Arbor, Michigan • Omaha, Nebraska • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 25, 2026, 11:47 AM EDT
Completed Phase 4 Interventional Results available

BK Treatment Study

NCT01034176
View directory record Official record
Conditions
BK Viremia
Interventions
levofloxacin, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Boston, Massachusetts • Burlington, Massachusetts • Worcester, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 25, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI

NCT02182440
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
recAP, Placebo
Biological · Other
Lead sponsor
AM-Pharma
Industry
Eligibility
18 Years to 85 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • Tampa, Florida • Idaho Falls, Idaho + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 25, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

NCT01727089
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma
Interventions
Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
28
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 25, 2026, 11:47 AM EDT
Withdrawn Phase 2 Interventional

BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer

NCT00040989
View directory record Official record
Conditions
Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer
Interventions
BAY 56-3722, enzyme inhibitor therapy
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
26
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 25, 2026, 11:47 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function

NCT07763418
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Golcadomide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 84 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Chandler, Arizona • Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 11:47 AM EDT